HIV prevalence in transgender women and cisgender men who have sex with men in sub-Saharan Africa 2010-2022: a meta-analysis

Oliver Stevens[1§], Rebecca L. Anderson[1], Keith Sabin[2], Sonia Arias Garcia[2], Elizabeth Fearon[3], Kingsley Manda[4], Wame Dikobe[5], Lloyd Mulenga[6], Neena M. Philip[7], Mathieu Maheu-Giroux[8], Jinkou Zhao[9], Mary Mahy[2], Jeffrey W. Imai-Eaton[1,10]

1 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom
2 Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS), Geneva, Switzerland
3 University College London, London, United Kingdom
4 Malawi National Statistics Office, Zomba, Malawi
5 FHI360, Gaborone, Botswana
6 Zambia Ministry of Health, Lusaka, Zambia
7 ICAP, Columbia University Mailman School of Public Health, New York, New York, USA
8 Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Canada
9 The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
10 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

§ Corresponding author
OS: o.stevens@imperial.ac.uk
RLA: Rebecca.anderson21@imperial.ac.uk
KS: sabink@unaids.org
SAG: ariasgarcias@unaids.org
EF: e.fearon@ucl.ac.uk
KM: mandakingsley@yahoo.com
WD: wdikobe@fhi360.org
LM: lloyd.mulenga@moh.gov.zm

MMG: mathieu.maheu-giroux@mcgill.ca
JZ: Jinkou.Zhao@theglobalfund.org
MM: mahym@unaids.org
JWI-E: Jeffrey.eaton@imperial.ac.uk

Corresponding author:
Oliver Stevens
St. Mary's Hospital Campus Norfolk Place London W2 1PG United Kingdom
o.stevens@imperial.ac.uk

Keywords: HIV-1; Transgender persons; Homosexuality, Male; Sexual and Gender Minorities; Africa

Pre-print available at

https://www.medrxiv.org/content/10.1101/2023.11.09.23298289v1

Abstract

Introduction: The Global AIDS Strategy 2021-2026 calls for equitable access to HIV services for all populations. Transgender people have been marginalised and experience disproportionate risk of HIV infection in sub-Saharan Africa (SSA) and data to guide HIV programmes are severely limited. Surveillance data among cisgender men who have sex with men (cis-MSM) are comparatively abundant. We assessed whether HIV prevalence among cis-MSM was correlated with HIV prevalence among transgender women.

Methods: Data from key population surveys conducted in SSA between 2010-2022 were identified from existing databases and survey reports. Studies that collected HIV prevalence on both transgender women and cis-MSM populations were analysed with random effect meta-analysis to estimate the ratio of HIV prevalence among cis-MSM:transgender women.

Results: Twenty-one studies were identified encompassing 8,476 transgender women and 24,102 cis-MSM. Median HIV prevalence among transgender women was 23.5% (interquartile range [IQR] 11.5-39.8%) and 16.2% (IQR 8.1-26.8%) among cis-MSM. HIV prevalence among transgender women was 50% higher than in cis-MSM (prevalence ratio 1.48 95CI 1.25-1.76). HIV prevalence among transgender women was highly correlated with year/province-matched HIV prevalence among cis-MSM (R^2=0.60), but poorly correlated with year/province-matched total population HIV prevalence (R^2=0.01).

Conclusion: Transgender women experience a significantly greater HIV burden than cis-MSM in SSA, underscoring the need for HIV services addressing the disproportionate vulnerability experienced by transgender women. Further bio-

behavioural surveys focused on determinants of HIV infection, treatment uptake, and risk behaviours among transgender people, distinct from cis-MSM, will improve understanding of HIV risk and vulnerabilities.

Introduction

The Global AIDS Strategy 2021-2026 calls for equitable and equal access to HIV prevention and treatment services for all to reduce HIV incidence and end HIV/AIDS as a public health threat by 2030[1]. The Strategy has motivated renewed focus to quantify population size, HIV prevalence, ART coverage, and new HIV infections among key populations in sub-Saharan Africa (SSA) to reduce inequality in the global HIV/AIDS response.

Transgender people experience a HIV risk environment wherein the combination of exposure to efficient HIV transmission routes and socio-structural risk factors result in disproportionate HIV burden[2–5]. Societal marginalisation, criminalisation, and stigma have impeded collection of robust HIV surveillance data among key populations in sub-Saharan Africa[6–8]. Global systematic reviews of HIV epidemiology among transgender people disproportionately reflect data outside SSA[4,5]. Only eleven SSA countries have population size estimates for transgender women, twenty countries have surveillance data on HIV prevalence, and nine have ART coverage data[9].

HIV prevalence data for men who have sex with men (MSM) in SSA are more widely available. Over 350 HIV prevalence estimates have been measured since 2010 across 32 of 38 SSA countries[9]. While cis-MSM and transgender women have distinct vulnerabilities to HIV[10,11], studies in SSA indicate that HIV epidemiology in these two populations is linked: transgender women are recruited by cis-MSM into surveys using social and sexual network recruitment[12,13]; transgender women most often report male sexual partners and receptive anal sex[12,14,15]; phylogenetic analysis indicates HIV transmission clustering between transgender women and cis-MSM[16,17]; and qualitative data indicate that some transgender people identify as

MSM[18,19]. Many surveillance studies primarily collecting data among cis-MSM have also included transgender people, providing a source of data in the absence of studies explicitly aiming to recruit transgender people.[20,21] We sought to meta-analyse relative HIV prevalence between cis-MSM and transgender women. This may be used to highlight the high HIV burden among transgender women in settings that lack surveillance data among this key population.

Methods

We extracted data on HIV prevalence among transgender people and cis-MSM between 2010-2022 in sub-Saharan Africa from UNAIDS Global AIDS Monitoring[22], The Global Fund surveillance database, US Centers for Disease Control and Prevention key population surveillance databases, and literature searches[9]. Studies that reported estimates of HIV prevalence for cis-MSM and any transgender population (as defined by study authors; Supplementary Table S1) in the same study were considered for inclusion. Tabulations of relevant data not reported in study publications were shared by the authors of Fearon et al.[13], Keshinro et al.[24], and Malawi 2019-20, Botswana 2017, and Zambia 2021 Biobehavioural Surveys[25–27].

HIV prevalence data were pooled and weighted proportional to the number of individuals tested. Where studies reported HIV prevalence for more than one transgender population, HIV prevalence among transgender women only was included in the meta-analysis. Log-normal random-effects meta-analysis was used to calculate pooled prevalence ratios (PRs) for HIV prevalence among transgender women compared to cis-MSM. Estimates were calculated separately for Eastern and Southern Africa (ESA) and Western and Central Africa (WCA) regions, and across all sub-Saharan Africa using nested study, country, and area random effects. We conducted a sensitivity analysis that included a fixed effect for calendar year, centred

at the mean year of study. Analyses were conducted in R 4.1.2[28], using the *metafor* package[29].

Province-level estimates of sex-specific total population HIV prevalence were extracted from UNAIDS estimates and projected backward 2000-2020 parallel to national-level HIV prevalence trajectories.[30,31] Four additional observations of HIV prevalence among transgender women[14,35–37] were included in in correlation analysis with total population HIV prevalence, which had been excluded from cis-MSM prevalence ratios meta-analysis because they lacked matching cis-MSM HIV prevalence estimates.

This study received ethical approval from the Imperial College Research and Ethics Committee (#6473559). Data are available at https://doi.org/10.5281/zenodo.10838437

Results

Twenty-one studies (11 in ESA and 10 in WCA) were included in the analysis, encompassing 8,476 transgender women and 24,102 cis-MSM (Supplementary Table S1). Eleven studies were from journal publications and ten were identified from grey literature including biobehavioural survey (BBS)[38] and PLACE study[39] reports. The median denominator for HIV prevalence among transgender women was 89 (IQR 35-235) and 368 (IQR 198-426) for cis-MSM. HIV status was ascertained by serological assays in all studies. Median HIV prevalence among transgender women in ESA was 25.0% (IQR 10.5-42.2%) and 23.3% (IQR 14.1-35.2%) in WCA. Median HIV prevalence among cis-MSM in ESA was 15.2% (IQR 8.8-24.6%) and 17.0% (IQR 7.8-27.5%) in WCA.

Pooled across sub-Saharan Africa, HIV prevalence in transgender women was 1.48 times higher (95%CI 1.25-1.76) than in cis-MSM (Figure 1). In ESA, prevalence among transgender women was 1.49 times higher than cis-MSM (95%CI 1.26-1.75) and in WCA 1.38 times higher (95%CI 0.92-2.07). In sensitivity analysis, HIV prevalence ratio declined 6% per year, but this was not statistically significant (annual PR 0.94; 95%CI 0.89-1.00).

HIV prevalence among transgender women was highly correlated with study-matched cis-MSM HIV prevalence (Figure 2; R^2=0.60) and poorly correlated with province/year-matched total population HIV prevalence (R^2=0.01). Relative to venue- and convenience-based sampling methods, studies using network-sampling methods did not estimate a significantly different pooled HIV prevalence ratio (Supplementary Table S1; PR 1.06 95%CI 0.72-1.56).

One-third of studies (6/21) included, or did not specifically exclude, transgender men in the sampled transgender population and were excluded from the primary meta-analysis. In sensitivity analysis excluding studies that reported combined HIV prevalence for transgender women and men, the estimated prevalence ratio was slightly higher (SSA PR: 1.63, 95%CI 1.36-1.96).

Discussion

We identified twenty-five studies that measured HIV prevalence among transgender women, a large increase from ten African studies included in a 2022 systematic review[40]. HIV prevalence was 50% higher among transgender women than cis-MSM in sub-Saharan Africa, providing further evidence of HIV vulnerability distinct from cis-MSM. Previous studies[4,5,41] have identified substantial HIV burden among transgender women, which this meta-analysis supports both in absolute terms and relative to cis-MSM. HIV service needs for transgender women are increasingly

recognised in HIV programmes in sub-Saharan Africa and are identified in the National Strategic HIV/AIDS Plans of sixteen countries[42], increasing from ten in 2018[43]. Our updated analysis included 21 studies compared to 8 studies identified in a 2017 review by Poteat et al.[20] (a more recent 2023 review by Kloek et al.[41] identified 10 studies among TGW but did not compare HIV prevalence with that among cis-MSM). Among those studies available in 2017, the prevalence ratio was 1.75 (95%CI 1.54-2.00), compared to 1.48 in this analysis.

We did not report pooled estimates of HIV prevalence among transgender women or relative risk of HIV infection compared to the total population[4,5]. Firstly, the relative risk of HIV infection in key populations varies with total population HIV prevalence in SSA. Summarising a single relative risk of infection decouples the key population epidemiology in a setting from the HIV epidemic in the total population. In WCA, cis-MSM HIV prevalence can be 100-fold higher than male total population prevalence, while in ESA it may be similar to, or lower than, that in the total population[9]. Second, total population HIV prevalence is poorly correlated with cis-MSM HIV prevalence, particularly in WCA where neighbouring countries with similar generalised HIV epidemics can have disparate key population epidemics[9,44]. Instead, we found a consistently higher risk of HIV infection in transgender women compared to cis-MSM. These estimates should be viewed as interim estimates to support programme planning in settings that lack dedicated HIV surveillance, and should not obviate the need for transgender-specific surveillance nor to further discourse that the programmatic needs of transgender people can be wholly met through cis-MSM programmes.[45] Recognising the additional HIV burden experienced by transgender women and their specific health needs (e.g. gender-affirming hormone therapy), while identifying common needs among sexual and gender minorities (e.g. stigma

and gender-based violence interventions) is an important strategy to ensure effective services reach those who need them in an era of constrained resources for key population programmes.

We were unable to estimate the relative HIV prevalence among transgender men relative to other populations, though limited data indicated that transgender men may have a lower prevalence of HIV infection than transgender women or cis-MSM (Supplementary Table S2)[16,51] Of six studies in this analysis that did not exclude transgender men, four included recent oral or anal sex with a man as an inclusion criterion. Though data across SSA are limited, they indicate that cis-women are more likely to be partners of transgender men than cis-MSM or other transgender men[26,46,47]. Transgender men are likely, therefore, to be excluded from biological surveillance if all transgender populations are associated with the same HIV risk behaviours as cis-MSM.

We retained three studies that did not specify which transgender population(s) were recruited in the main analysis[25,48,49]. Sexual behaviour data collected in each study indicated that transgender participants overwhelmingly reported male sexual partners and receptive anal intercourse. All three studies were recent, published since 2020, and with large sample sizes. Sensitivity analysis indicates that their inclusion had only a marginal impact on the estimated relative risk of HIV infection, and we feel that their inclusion alongside studies that explicitly recruited transgender women is justified. Survey data on gender identity were often ambiguous, necessitating its removal from analysis further reducing sample sizes. Further research into accurately recording gender identity across diverse settings[19] would improve gender identification in key population surveys and enhance comparability across studies[46,50].

Few studies have measured treatment coverage or viral load suppression among transgender people, and only a subset is laboratory confirmed[9]. While we identified that transgender women are at increased risk of HIV infection, it was not possible to estimate ART coverage or access to treatment services either in absolute terms or relative to cis-MSM. This remains a key data gap in monitoring the objectives laid out by the Global AIDS Strategy.

Interpretation of this analysis is subject to several limitations. Firstly, we did not differentiate between studies whose primary objective was transgender surveillance[12,15,24,27,49,51–58], and those that reported transgender participants alongside the primary objective of cis-MSM surveillance[13,25,26,48,59–61], which may disproportionately recruit transgender people who socialise with cis-MSM. These data may overstate the similarities between the two populations as phylogenetic clustering studies indicate extensive transmission between cis-MSM/TGW and the heterosexual-identifying population[62]. Second, insufficient age-specific HIV prevalence data were available to estimate age-adjusted prevalence risk ratios which may lead to underestimated prevalence ratios.

Conclusion

Transgender women have 50% higher HIV prevalence than cis-MSM in SSA and, therefore, transgender women and cis-MSM should not be considered as a single risk population. HIV prevalence among transgender women is highly correlated with cis-MSM prevalence, and cis-MSM HIV prevalence may help inform assessment of HIV prevalence among transgender women in settings that lack dedicated surveillance. Studies estimating the treatment cascade among transgender women and men are a priority to quantify progress towards equitable HIV service access

and enable HIV programmes to meet the prevention and treatment needs of transgender people.

Competing interests

None

Authors' contributions

OS, KS, MM, and JWI-E conceptualised the study. KS, SAG, and JZ curated key population survey databases. EF, TC, KM, WD, and LM provided additional unpublished data from surveillance studies. OS and RA reviewed primary source documents, deduplicated data, and extracted data. OS analysed the data and wrote the first draft of the manuscript. All authors contributed to interpretation of results and edited the manuscript for intellectual content. All authors read and approved the final version of the manuscript for submission.

Acknowledgments and funding

This research was supported by UNAIDS, the Bill and Melinda Gates Foundation (OPP1190661), National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R01-AI136664, and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.

3839

iso3 | Author | Area	TGW n/N	cis-MSM n/N	Prevalance ratio [95% CI]
AGO | Angola MoH | Angola	8/89	20/1016	4.57 [2.07, 10.07]
BWA | Botswana MoH | Botswana	6/12	110/736	3.35 [1.85, 6.04]
KEN | Sandfort et al. | Kisumu	8/32	20/137	1.71 [0.83, 3.53]
KEN | Smith et al. | Nairobi	28/70	151/522	1.38 [1.01, 1.90]
LSO | Poteat et al. | Maputsoe and Maseru	42/71	130/455	2.07 [1.63, 2.64]
MOZ | Mozambique MoH | Beira, Dondo	2/22	41/290	0.64 [0.17, 2.48]
MOZ | Mozambique MoH | Cidade de Maputo	8/23	3/61	7.07 [2.05, 24.37]
MOZ | Mozambique MoH | Inchope, Chimoio, Manica	3/41	6/96	1.17 [0.31, 4.46]
MOZ | Mozambique MoH | Tete, Changara, Moatize	2/32	1/70	4.38 [0.41, 46.51]
MWI | Sandfort et al. | Blantyre	12/38	15/84	1.77 [0.92, 3.41]
MWI | Malawi MoH | Blantyre	14/88	57/352	0.98 [0.57, 1.68]
MWI | Malawi MoH | Karonga	0/18	2/67	0.91 [0.04, 19.23]
MWI | Malawi MoH | Lilongwe	25/190	29/392	1.78 [1.07, 2.95]
MWI | Malawi MoH | Mangochi	21/94	53/204	0.86 [0.55, 1.34]
MWI | Malawi MoH | Nkhatabay	6/62	10/122	1.18 [0.45, 3.10]
MWI | Malawi MoH | Zomba	7/88	27/288	0.85 [0.38, 1.88]
MWI | Poteat et al. | Lilongwe	12/75	40/263	1.05 [0.58, 1.90]
RWA | Rwema et al. | Kigali	10/106	64/630	0.93 [0.49, 1.75]
SWZ | eSwatini MoH | eSwatini	7/17	84/415	2.03 [1.12, 3.70]
SWZ | Poteat et al. | Mbabane	17/120	38/204	0.76 [0.45, 1.29]
ZAF | Fearon et al. | Johannesburg	20/44	90/233	1.18 [0.82, 1.69]
ZAF | Sandfort et al. | Cape Town	13/30	31/109	1.52 [0.92, 2.53]
ZAF | Sandfort et al. | Soweto	25/36	59/135	1.59 [1.19, 2.12]
ZAF | Jobson et al. | Cape Town	12/21	47/150	1.82 [1.17, 2.83]
ZAF | Sullivan et al. | Cape Town/Port Elizabeth	13/22	110/263	1.41 [0.97, 2.06]
ZMB | Zambia MoH | Kitwe	14/97	23/249	1.56 [0.84, 2.91]
ZMB | Zambia MoH | Livingstone	11/114	37/339	0.88 [0.47, 1.67]
ZMB | Zambia MoH | Lusaka	38/136	71/310	1.22 [0.87, 1.71]
ZMB | Zambia MoH | Solwezi	8/106	11/190	1.30 [0.54, 3.14]
ZWE | Zimbabwe MoH | Harare	78/279	71/416	1.64 [1.23, 2.17]
ZWE | Zimbabwe MoH | Bulawayo	14/56	177/760	1.07 [0.67, 1.72]
Eastern and Southern Africa regional estimate (Q = 61.79, df = 30, p < .01)			1.49 [1.26, 1.75]
BFA | Poteat et al. | 2 cities*	3/108	18/552	0.85 [0.26, 2.84]
BFA | Stahlman et al. | 2 cities*	0/5	1/22	2.00 [0.08, 52.29]
CIV | Poteat et al. | 4 cities**	76/298	61/766	3.20 [2.35, 4.36]
CIV | Stahlman et al. | 4 cities**	16/68	4/55	3.24 [1.15, 9.12]
GHA | Ghana MoH | Ghana	9/31	651/3723	1.66 [0.95, 2.89]
GMB | Poteat et al. | Banjul	2/4	18/200	5.56 [1.90, 16.27]
LBR | Liberia MoH | Montserrado	58/203	194/471	0.69 [0.54, 0.88]
LBR | Liberia MoH | Grand Gedeh	0/32	2/63	0.48 [0.02, 10.44]
LBR | Liberia MoH | Grand Bassa	23/55	20/30	0.63 [0.42, 0.94]
MLI | Hakim et al. | Bamako	41/165	37/387	2.60 [1.73, 3.90]
NGA | Nigeria MoH | Abia	57/369	39/369	1.46 [1.00, 2.14]
NGA | Nigeria MoH | Akwa Ibom	84/369	78/370	1.08 [0.82, 1.42]
NGA | Nigeria MoH | Anambra	18/372	64/372	0.28 [0.17, 0.46]
NGA | Nigeria MoH | Benue	45/372	78/372	0.58 [0.41, 0.81]
NGA | Nigeria MoH | Gombe	54/363	27/368	2.03 [1.31, 3.14]
NGA | Nigeria MoH | Kaduna	35/372	62/372	0.56 [0.38, 0.83]
NGA | Nigeria MoH | Kano	26/372	40/372	0.65 [0.41, 1.04]
NGA | Nigeria MoH | Lagos	107/372	102/372	1.05 [0.83, 1.32]
NGA | Nigeria MoH | Nassarawa	55/372	82/372	0.67 [0.49, 0.91]
NGA | Nigeria MoH | Oyo	173/372	138/372	1.25 [1.06, 1.49]
NGA | Nigeria MoH | Rivers	79/229	133/372	0.96 [0.77, 1.21]
NGA | Nigeria MoH | Taraba	42/256	83/314	0.62 [0.45, 0.87]
NGA | Keshinro et al. | Abuja	60/151	526/1460	1.10 [0.90, 1.36]
NGA | Keshinro et al. | Lagos	63/88	261/469	1.29 [1.10, 1.50]
SEN | Poteat et al. | Dakar	74/199	147/528	1.34 [1.06, 1.68]
SLE | Sierra Leone MoH | Sierra Leone	23/532	19/559	1.27 [0.70, 2.31]
TGO | Poteat et al. | Kara and Lome	9/51	53/626	2.08 [1.09, 3.98]
TGO | Stahlman et al. | Kara and Lome	2/9	3/42	3.11 [0.60, 16.01]
Western and Central Africa regional estimate (Q = 205.28, df = 27, p < .01)			1.38 [0.92, 2.07]
Sub-Saharan Africa regional estimate (Q = 296.59, df = 58, p < .01)			1.48 [1.25, 1.76]



Figure 1: Forest plot comparing HIV prevalence ratios in transgender women (TGW) and cis-gendered men-who-have-sex-with-men (cis-MSM).

* Bobo-Dioulasso and Ouagadougou

** Abidjan, Bouake, Gagnoa, and Yamoussoukro



Figure 2: Comparison of HIV prevalence among transgender women and cis-gender men-who-have-sex-with men (cis-MSM) (left) and HIV prevalence among transgender women compared to HIV prevalence among all women aged 15-49 years (right). The dotted line represents the line of equality is (y=x). Colour of data points represents the UNAIDS region of the study country.

Supplementary Table S1: Studies included in meta-analysis of HIV prevalence in transgender women (TGW) and cis-gendered men who have sex with men (cis-MSM)

Study	Year of publication	Country	Year of data collection	Recruitment method	Transgender women inclusion criterion	TGW prevalence (%; n/N)	cis-MSM prevalence (%; n/N)
Stahlman et al. [15]	2016	Burkina Faso	2013	RDS	Identified as female or transgender, assigned male sex at birth, and reported having had insertive or receptive anal sex with a man in the past 12 months	0.0% (0/5)	4.5% (1/22)
		Côte d'Ivoire	2015			23.5% (16/68)	7.3% (4/55)
		Togo	2013			22.2% (2/9)	7.1% (3/42)
Keshinro et al. [24]	2016	Nigeria	2016	RDS	Identified as female, assigned male sex at birth, and reported having had insertive or receptive anal sex with a man in the past 12 months	51.5% (123/239)	40.7% (786/1929)
Botswana MoH [26]	2017	Botswana	2017	RDS	Identified as a woman, formerly or currently biologically male	50.0% (6/12)	14.9% (110/736)
Ghana MoH [61]	2017	Ghana	2017	RDS	Identified as a woman, biologically male, and have had anal or oral sex with another man in the last 12 months	28.1% (9/31)	17.4% (650/3723)
Mozambique MoH [51]	2018	Mozambique	2017	PLACE	Identified as a woman or transgender, assigned male at birth	12.7% (15/118)	9.9% (51/517)
Poteat et al. [12]	2017	Burkina Faso	2013	RDS	Self-identified as transgender or female/woman, and assigned male sex at birth	2.8% (3/108)	3.3% (18/552)
		Côte d'Ivoire	2016			25.5% (76/298)	8.0% (61/766)
		Gambia	2011			50.0% (2/4)	9.0% (18/200)
		Lesotho	2014			59.2% (42/71)	28.6% (130/455)
		Malawi	2012			16.0% (12/75)	15.2% (40/263)
		Senegal	2015			37.2% (74/199)	27.8% (147/528)
		Eswatini	2011			14.2% (17/120)	18.6% (38/204)
		Togo	2013			17.6% (9/51)	8.5% (53/626)
Angola MoH [53]	2018	Angola	2017	PLACE	Identified as a woman, and	9.0% (8/89)	2.0% (20/1016)

					assigned male at birth		
Hakim et al. [52]	2018	Mali	2015	RDS	Identified as a woman, assigned male sex at birth, and reported having had insertive or receptive anal sex with a man in the past 6 months	24.3% (9/37)	9.7% (12/124)
Jobson et al. [59]	2018	South Africa	2017	Snowball	Self-identified as female or transgender, biologically male, and as having sex with men	57.1% (12/21)	31.3% (47/150)
Sandfort et al. [60]	2019	Kenya	2016	Convenience	Did not identify as male, assigned male sex at birth, and ever had sex with a man	25.0% (8/32)	14.6% (20/137)
		Malawi	2016			31.6% (12/38)	17.9% (15/84)
		South Africa	2016			57.6% (38/66)	36.9% (90/244)
Liberia MoH [63]	2019	Liberia	2018	RDS	No inclusion criterion provided	27.6% (80/290)	37.9% (240/633)
Fearon et al. [13]	2020	South Africa	2017	RDS	Assigned male at birth and current identity was female or transgender. Sex with a man in last 12 months	44.6% (20/44)	38.6% (90/233)
Malawi MoH [25]	2020	Malawi	2020	RDS	Self-identified as female or transgender. Engaged in sexual activities with other men in the past 12 months	13.5% (73/540)	12.5% (178/1425)
Nigeria MoH [49]	2020	Nigeria	2020	Venue-based	Identifies him/herself as a transsexual and undertakes sexual activity with a man	18.5% (775/4190)	21.1% (926/4397)
Rwema et al. [54]	2020	Rwanda	2018	RDS	Self-identified as transgender or a woman, assigned male sex at birth, and reported having had insertive or receptive anal sex with a man in the past 12 months	9.4% (10/106)	10.2% (64/630)
eSwatini MoH [48]	2021	Eswatini	2020	RDS	Identified as female. Report have insertive or receptive anal sex with a man in the past 12 months	41.2% (7/17)	20.2% (84/415)

Smith et al. [55]	2021	Kenya	2017	RDS	Male sex assignment at birth, self-identify as female or transgender, and having had consensual anal or oral sexual activity with a man in the previous 12 months	40.0% (28/70)	28.9% (151/522)
Sullivan et al. [56]	2021	South Africa	2016	Convenience	Male sex at birth and current gender identity as female or transgender, and report having had insertive or receptive anal sex with a man in the past 12 months	59.1% (13/22)	41.8% (110/263)
Harris et al. [57]	2022	Zimbabwe	2019	RDS	Born biologically male; self-identifed as a woman, transgender, or genderqueer, and engaged in anal or oral sex with a man in the past 12 months	27.5% (92/335)	21.1% (248/1176)
Sierra Leone MoH [58]	2022	Sierra Leone	2021	RDS	A woman who had a gender identity that is different from her sex at birth	4.7% (23/487)	4.2% (18/430)
Zambia MoH [64]	2023	Zambia	2021	RDS	Self-identified as a woman, biologically male at birth and self-reported anal or oral sex with biological male in past 6 months	17% (77/453)	13.5% (147/1088)

RDS=respondent driven sampling [38]; PLACE=Priorities for Local AIDS Control Efforts [39]

Study	Area	Year	HIV prevalence (%)				
			TGM	TGW	cis-MSM	15-49 women	15-49 men
Benin MoH [36]	Benin	2020	**9.5**	**26.4**	*7* [49]	*1.1*	*0.5*
Mujugira et al. [42]	Kampala, Uganda	2020	**4.1**	*20.0* [17]	*12.7* [63]	*7.4*	*4.8*
Botswana MoH [27]	Botswana	2017	**6.8**	**45.5**	**14.9**	*26.2*	*16*
Malawi MoH [43]	Malawi	2021	**23.9**	**62.3**	*12.5* [26]	*9.3*	*5.6*
Sierra Leone [40]	Sierra Leone	2021	**1.11**	**4.36**	**3.4**	*1.8*	*1*

Supplementary Table S2: Estimates of HIV prevalence among transgender men (TGM) compared with transgender women (TGW), cis-gendered men who have sex with men (cis-MSM), and 15-49 total population. In each row, estimates in bold are from the same study indicated in the 'Study' column. Transgender women and cis-MSM estimates in italics are the best available comparator estimates from other studies. Total population HIV prevalence estimates are from UNAIDS estimates derived using Spectrum and Naomi models.

References

1 United Nations. End Inequalities. End AIDS. Global AIDS Strategy 2021-2026 | UNAIDS. https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy (accessed May 5, 2021).

2 Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People. J Acquir Immune Defic Syndr. 2016; **72**: S210–9.

3 Singer M, Bulled N, Ostrach B, Mendenhall E. Syndemics and the biosocial conception of health. The Lancet. 2017; **389**: 941–50.

4 Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: A systematic review and meta-analysis. *Lancet Infect Dis* 2013; **13**: 214–22.

5 Stutterheim SE, Van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis. PLoS One. 2021; **16**. DOI:10.1371/journal.pone.0260063.

6 Stannah J, Dale E, Elmes J, *et al.* HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. *Lancet HIV* 2019; **6**: e769–87.

7 Degenhardt L, Peacock A, Colledge S, *et al.* Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* 2017; **5**: e1192–207.

8 Garcia SA, Chen J, Calleja JG, *et al.* Availability and quality of surveillance and survey data on HIV prevalence among sex workers, men who have sex with

men, people who inject drugs, and transgender women in low- And middle-income countries: Review of available data (2001-2017). *JMIR Public Health Surveill* 2020; **6**. DOI:10.2196/21688.

9 Stevens O, Sabin K, Garcia SA, *et al.* Key population size, HIV prevalence, and ART coverage in sub-Saharan Africa: systematic collation and synthesis of survey data, 2010-23. *Lancet Global Health* 2024; **12**. DOI:10.1016/S2214-109X(24)00236-5.

10 Poteat TC, van der Merwe LLA, Sevelius J, Keatley JA. Inclusion as illusion: erasing transgender women in research with MSM. J Int AIDS Soc. 2021; **24**. DOI:10.1002/jia2.25661.

11 Perez-Brumer AG, Oldenburg CE, Reisner SL, Clark JL, Parker RG. Towards 'reflexive epidemiology': Conflation of cisgender male and transgender women sex workers and implications for global understandings of HIV prevalence. *Glob Public Health* 2016; **11**: 849–65.

12 Poteat T, Ackerman B, Diouf D, *et al.* HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis. *PLoS Med* 2017. DOI:10.1371/journal.pmed.1002422.

13 Fearon E, Tenza S, Mokoena C, *et al.* HIV testing, care and viral suppression among men who have sex with men and transgender individuals in Johannesburg, South Africa. *PLoS One* 2020; **15**: e0234384.

14 King R, Nanteza J, Sebyala Z, *et al.* HIV and transgender women in Kampala, Uganda–Double Jeopardy. *Cult Health Sex* 2019; **21**: 727–40.

15 Stahlman S, Liestman B, Ketende S, *et al.* Characterizing the HIV risks and potential pathways to HIV infection among transgender women in Cote d'Ivoire, Togo and Burkina Faso. *J Int AIDS Soc* 2016; **19**. DOI:10.7448/IAS.19.3.20774.

16 Sivay M V., Palumbo PJ, Zhang Y, *et al.* Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study. *Clinical Infectious Diseases* 2021; **73**: 60–7.

17 Nduva GM, Otieno F, Kimani J, *et al.* Quantifying rates of HIV-1 flow between risk groups and geographic locations in Kenya: A country-wide phylogenetic study. *Virus Evol* 2022; **8**: 1–14.

18 Sandfort TGM, Bos H, Reddy V. Gender Expression and Mental Health in Black South African Men Who Have Sex with Men: Further Explorations of Unexpected Findings. *Arch Sex Behav* 2018. DOI:10.1007/s10508-018-1168-9.

19 Sandfort TGM, Dominguez K, Chimwaza Y, Mbeda C, Lucas J, Hamilton EI. The Reliability of Assessing Gender Minority Status Based on Gender Identity and Sex Assigned at Birth in the African Context: Findings from the HIV Prevention Trials Network 075 Study. *https://home.liebertpub.com/lgbt* 2025; **12**: 378–85.

20 Poteat T, Ackerman B, Diouf D, *et al.* HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have

sex with men in 8 African countries: A cross-sectional analysis. *PLoS Med* 2017. DOI:10.1371/journal.pmed.1002422.

21 Korenromp EL, Sabin K, Stover J, *et al.* New HIV infections among key populations and their partners in 2010 and 2022, by world region - a multi-sources estimation. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2023.

22 UNAIDS. Global AIDS Monitoring 2022. 2022. https://www.unaids.org/en/global-aids-monitoring (accessed Feb 18, 2022).

23 UNAIDS. Key Populations Atlas. https://kpatlas.unaids.org/dashboard (accessed Nov 27, 2021).

24 Keshinro B, Crowell TA, Nowak RG, *et al.* High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. In: Journal of the International AIDS Society. International AIDS Society, 2016. DOI:10.7448/IAS.19.1.21270.

25 Ministry of Health & National Statistics Office. Malawi Biological and Behavioural Surveillance Survey 2019-2010. 2020.

26 Botswana Ministry of Health. Behavioral and Biological Surveillance Survey of HIV/STI among select high-risk subpopulations in Botswana. 2017.

27 Zambia Ministry of Health. BIOBEHAVIORAL SURVEY AMONG MEN WHO HAVE SEX WITH MEN IN ZAMBIA. 2021.

28 R Core Team. R: A language and environment for statistical computing. 2021.

29 Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010.

30 UNAIDS. Naomi. https://naomi.unaids.org/login (accessed June 23, 2025).

31 Stover J, Glaubius R. Methods and Assumptions for Estimating Key HIV Indicators in the UNAIDS Annual Estimates Process. *J Acquir Immune Defic Syndr (1988)* 2024; **95**: E5–E12.

32 UNAIDS. HIV sub-national estimates viewer. 2021. https://naomi-spectrum.unaids.org/ (accessed May 12, 2022).

33 Eaton JW, Brown T, Puckett R, *et al.* The Estimation and Projection Package Age-Sex Model and the r-hybrid model: New tools for estimating HIV incidence trends in sub-Saharan Africa. *AIDS* 2019; **33**: S235–44.

34 Stover J, Glaubius R, Mofenson L, *et al.* Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. *AIDS* 2019; **33**: S227–34.

35 Cote d'Ivoire Ministry of Health. Rapport de l'étude pour l'identification des besoins spécifiques en matière de prévention et prise en charge IST-VIH/SIDA chez les personnes transgenres a Abidjan. 2019.

36 Mali Ministry of Health. Analyse de la situation des personnes transgenres au Mali en relation avec l'infection a VIH et la SIDA. 2019.

37 Benin Ministry of Health. Enquete bio-comportementale, cartographie, et estimation de la taille des transgenres au Benin. 2020.

38 UNAIDS, FHI 360, WHO, CDC, PEPFAR. Biobehavioural Survey Guidelines For Populations At Risk For HIV. 2017.

39 Weir S. Priorities for Local AIDS Control Efforts (PLACE). 2019 https://www.measureevaluation.org/resources/publications/ms-19-173/at_download/document.

40 Kloek M, Bulstra CA, van Noord L, Al-Hassany L, Cowan FM, Hontelez JAC. HIV prevalence among men who have sex with men, transgender women and cisgender male sex workers in sub-Saharan Africa: a systematic review and meta-analysis. *J Int AIDS Soc* 2022; **25**. DOI:10.1002/JIA2.26022.

41 Kloek M, Bulstra CA, van Noord L, Al-Hassany L, Cowan FM, Hontelez JAC. HIV prevalence among men who have sex with men, transgender women and cisgender male sex workers in sub-Saharan Africa: a systematic review and meta-analysis. *J Int AIDS Soc* 2022; **25**: e26022.

42 Sherwood J, Lankiewicz E, Castellanos E, O'Connor N, Theron L, Restar A. Assessing inclusion of trans people in HIV national strategic plans: a review of 60 high HIV prevalence countries. *J Int AIDS Soc* 2021; **24**: e25837.

43 WHO. Focus on key populations in national HIV Strategic PLans in the Africa Region. 2018.

44 Hessou PHS, Glele-Ahanhanzo Y, Adekpedjou R, *et al.* Comparison of the prevalence rates of HIV infection between men who have sex with men (MSM) and men in the general population in sub-Saharan Africa: A systematic review and meta-analysis. *BMC Public Health* 2019; **19**: 1634.

45 Jessani A, Berry-Moreau T, Parmar R, Athanasakos A, Prodger JL, Mujugira A. Healthcare access and barriers to utilization among transgender and gender diverse people in Africa: a systematic review. *BMC Global and Public Health* 2024; **2**: 1–12.

46 Mujugira A, Kasiita V, Bagaya M, *et al.* “You are not a man”: a multi-method study of trans stigma and risk of HIV and sexually transmitted infections among trans men in Uganda. *J Int AIDS Soc* 2021; **24**. DOI:10.1002/jia2.25860.

47 Benin Ministry of Health. Analyse de la situation des transgenres en matiere de l’infection a VIH et le SIDA au Benin. 2017.

48 eSwatini Ministry of Health. Integrated biological-behavioural surveillance survey among female sex workers and men who have sex with men in eSwatini. 2021.

49 Nigeria Ministry of Health. Integrated Biological & Behavioural Surveillance Survey (IBBSS) among Key Populations in Nigeria. 2020.

50 Reisner SL, Biello K, Rosenberger JG, *et al.* Using a Two-Step Method to Measure Transgender Identity in Latin America/the Caribbean, Portugal, and Spain. *Arch Sex Behav* 2014; **43**: 1503–14.

51 Mozambique Ministry of Health. Mapeamento Programático e Prevalência de HIV entre Populações Chave em 5 Províncias de Moçambique: Estudo PLACE 2017. 2018; : 1–158.

52 Hakim AJ, Coy K, Patnaik P, *et al.* An urgent need for HIV testing among men who have sex with men and transgender women in Bamako, Mali: Low awareness of HIV infection and viral suppression among those living with HIV. *PLoS One* 2018; **13**: 1–14.

53 Angola Ministry of Health. Mapeamento Programático e Prevalência de VIH e outras ITS entre Populações Chave de Angola□: Estudo PLACE 2017. 2018.

54 Twahirwa Rwema JO, Lyons CE, Herbst S, *et al.* HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross sectional study. *J Int AIDS Soc* 2020; **23**: e25604.

55 Smith AD, Kimani J, Kabuti R, Weatherburn P, Fearon E, Bourne A. HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study. *Lancet HIV* 2021; **8**: e274–83.

56 Sullivan PS, Phaswana-Mafuya N, Baral SD, *et al.* HIV prevalence and incidence in a cohort of South African men and transgender women who have sex with men: the Sibanye Methods for Prevention Packages Programme (MP3) project. *J Int AIDS Soc* 2020; **23**. DOI:10.1002/jia2.25591.

57 Harris TG, Wu Y, Parmley LE, *et al.* HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampling. *Lancet HIV* 2022; **0**. DOI:10.1016/S2352-3018(21)00297-6.

58 Sierra Leone Ministry of Health. Integrated Biobehavioural Survey and population size estimation among FSW, MSM, PWID, TG, and PCS in Sierra Leone. 2021.

59 Jobson G, Tucker A, de Swardt G, *et al.* Gender identity and HIV risk among men who have sex with men in Cape Town, South Africa. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV* 2018; **30**: 1421–5.

60 Sandfort TGM, Dominguez K, Kayange N, *et al.* HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. *PLoS One* 2019. DOI:10.1371/journal.pone.0217501.

61 Ghana Ministry of Health. Ghana Men's Study II. 2017.

62 Sivay M V., Palumbo PJ, Zhang Y, *et al.* Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study. *Clin Infect Dis* 2021; **73**: 60–7.

63 Liberia Ministry of Health. Integrated bio-behavioural surveillance survey report of key popoulations in Liberia. 2019.

64 Hayes RJ, Donnell D, Floyd S, *et al.* Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART). *New England Journal of Medicine* 2019; **381**: 207–18.